Analysis

Dianthus Therapeutics, Inc. (DNTH) Stock Analysis

Dianthus Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to DNTH.

websiteDNTH/analysis/DNTH

Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to DNTH.

Stock profile

Ticker

DNTH

Asset type

Stock

Market cap

$4.51B

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Dianthus Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • DNTH primary listing
  • 87E
  • A3ERZ4

Latest Dianthus Therapeutics, Inc. news

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule

Dianthus Therapeutics to Participate in Two Investor Conferences

NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-gen...

LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis

NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, ...

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwr...

NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company ...

Research sections

Valuation

Review valuation context for Dianthus Therapeutics, Inc..

Future growth

Review future growth context for Dianthus Therapeutics, Inc..

Past performance

Review past performance context for Dianthus Therapeutics, Inc..

Financial health

Review financial health context for Dianthus Therapeutics, Inc..

Dividend

Review dividend context for Dianthus Therapeutics, Inc..

Management

Review management context for Dianthus Therapeutics, Inc..

Ownership

Review ownership context for Dianthus Therapeutics, Inc..

Other information

Review other information context for Dianthus Therapeutics, Inc..

Community

Review community context for Dianthus Therapeutics, Inc..